Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals
Abuknesha NR, O'Keefe JH, Qian F, Tintle NL, Lin Y, Sun Y, Qian HZ, Aisen PS, Albert CM, Aronson WJ, Asbeutah AAA, Bischoff-Ferrari HA, Budoff MJ, Burns NR, Cardenas CA, Carlsson CM, Chew EY, Cohen NJ, Fezeu LK, Liddell A, Galan P, Hull MA, Lan TH, Lin PY, Mengelberg A, Minihane AM, Quinn JF, Sanders TAB, Scholey A, Schoenfeld DA, Sprange K, Su KP, van Dyck CH, Van Hulle CA, Vauzour D, Weber C, Welty FK, Wittert G, Harris WS
Circulation. Arrhythmia and electrophysiology · 2 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Intramural NIH HHS
- Gobierno
- NHLBI NIH HHS
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-07-28 · Circ Arrhythm Electrophysiol · vol. 19 · número 8 · pág. e014785
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 0 citas · más que el 57% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 74 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Folate and B Vitamins Research · Atrial Fibrillation Management and Outcomes
- Palabras clave
- Eicosapentaenoic acid, Atrial fibrillation, Docosahexaenoic acid, Incidence (geometry), Odds ratio, Randomized controlled trial, Clinical trial, Relative risk
- MeSH
- humans, atrial fibrillation, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, treatment outcome, incidence, risk assessment, risk factors, middle aged, randomized controlled trials as topic
39 autores
- Nada Abuknesha (
- James Henry O’Keefe🇺🇸Saint Luke's Health System; Saint Luke's Hospital
- Frank Qian🇺🇸Boston Medical Center
- Nathan Tintle
- Yidie Lin🇨🇳Sichuan University; West China Hospital of Sichuan University
- Yue Sun🇨🇳Sichuan University; West China Hospital of Sichuan University
- Han‐Zhu Qian🇫🇷🇺🇸GlaxoSmithKline (France); GlaxoSmithKline (United States)
- Paul S. Aisen🇺🇸Southern States University
- Christine M. Albert🇺🇸Massachusetts General Hospital; Cedars-Sinai Smidt Heart Institute
- William J. Aronson🇺🇸University of California, Los Angeles; University of California System; VA Greater Los Angeles Healthcare System
- Abdul Aziz Asbeutah🇺🇸Beth Israel Deaconess Medical Center; UW Health University Hospital
- Heike A Bischoff-Ferrari🇨🇭University of Basel; Felix Platter-Hospital
- Matthew J. Budoff🇺🇸UCLA Medical Center; Harbor–UCLA Medical Center
- Nicholas R. Burns🇦🇺The University of Adelaide
- Cecilia A. Cardenas🇺🇸University of Wisconsin–Madison; William S. Middleton Memorial Veterans Hospital
- Cynthia M. Carlsson🇺🇸University of Wisconsin–Madison
- Emily Y. Chew🇺🇸National Eye Institute
- Neal J. Cohen🇺🇸University of Illinois Urbana-Champaign
- Léopold K. Fezeu🇫🇷Conservatoire National des Arts et Métiers; Inserm; Université Paris Cité; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement; Université Sorbonne Paris Nord; Sorbonne Paris Cité; Centre de Recherche Épidémiologie et Statistique
- Amana R. Liddell🇺🇸University of Southern California; University of California, Los Angeles; University of California System; VA Greater Los Angeles Healthcare System
- Pilar Galán🇫🇷Conservatoire National des Arts et Métiers; Inserm; Université Paris Cité; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement; Université Sorbonne Paris Nord; Sorbonne Paris Cité; Centre de Recherche Épidémiologie et Statistique
- Mark A. Hull🇬🇧St James's University Hospital
- Tsuo‐Hung Lan🇰🇷🇹🇼Ministry of Health and Welfare; National Yang Ming Chiao Tung University
- Pan-Yen Lin🇹🇼China Medical University
- Alexia Mengelberg🇳🇿Massey University
- Anne‐Marie Minihane🇬🇧University of East Anglia
- Joseph F. Quinn🇺🇸Oregon Health & Science University
- Thomas A.B. Sanders🇬🇧King's College London
- Andrew Scholey🇬🇧🇦🇺Northumbria University; Swinburne University of Technology
- David A. Schoenfeld🇺🇸Massachusetts General Hospital
- Kirsty Sprange🇬🇧University of Nottingham
- Kuan-Pin Su🇹🇼China Medical University; An-Nan Hospital
- Christopher H. van Dyck🇺🇸Yale University
- Carol A. Van Hulle🇺🇸University of Wisconsin–Madison
- David Vauzour🇬🇧University of East Anglia
- Claire Weber🇺🇸National Eye Institute
- Francine K. Welty🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Gary Wittert🇦🇺Royal Adelaide Hospital; South Australian Health and Medical Research Institute; The University of Adelaide
- William S. Harris🇺🇸University of South Dakota
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Recent meta-analyses of randomized controlled trials have raised concerns that treatment with omega-3 fatty acids may increase the risk of atrial fibrillation (AF). However, these meta-analyses included at most 8 trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 randomized controlled trials with AF incidence data, incorporating both published and unpublished data.
Methods
Eligible studies were randomized controlled trials investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months of treatment with EPA/DHA, participants ≥50 years of age, and, where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was the occurrence of new-onset AF. Our primary hypothesis was that risk for AF would simultaneously depend on both omega-3 dose (above or below 1500 mg/d) and background cardiovascular disease risk status, and that their combined impact on AF risk would be synergistic.
Results
A total of 35 randomized controlled trials (37 data sets; n=114 592) were included in this meta-analysis. Only studies including patients at high-risk for cardiovascular disease who were treated with high-doses of EPA/DHA (>1500 mg/d) showed a statistically significant increase in AF risk with a pooled odds ratio (OR) of 1.43 (95% CI, 1.14-1.79) and an absolute risk difference of 0.8% (0.40%-1.1%). None of the other 3 groups showed statistically significant levels of AF risk (odds ratios, 1.07 [high risk-low dose], 1.06 [low risk-low dose], and 1.03 [low risk-high dose]).
Conclusions
This meta-analysis suggests that high-dose EPA/DHA treatment is associated with an increased risk of AF in patients at high cardiovascular disease risk, whereas low-dose EPA/DHA does not appear to increase AF risk, even in high-risk populations. Further prospective studies are needed to evaluate any potential increased risk of higher doses balanced against potential benefits.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.